Completed
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source
Completed
Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
NCT06694701· Phase 2· Hellenic Institute for the Study of Sepsis· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411· Phase 3· Novo Nordisk A/S· Source
Completed
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.
NCT06173505· Phase 1/2· Xencor Inc.· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Genentech Inc.· Source
Recruiting
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
2023-505775-70-00· Phase 2· European Myeloma Network B.V.· Source
Active, not recruiting
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207· Phase 3· Novo Nordisk A/S· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to
Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma
(RRMM)
2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source
Active, not recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene
NCT05469178· Phase 1/2· Bergenbio ASA· Source
Completed
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Completed
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· Phase 2· Shionogi· Source
Active, not recruiting
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· Phase 2/3· Regeneron Pharmaceuticals· Source
Completed
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
2022-501451-87-00· Phase 1/2· Zhejiang Genfleet Therapeutics Co. Ltd.· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Completed
LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
NCT07361679· Phase 4· Alexandra Hospital, Athens, Greece· Source
Completed
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· Phase 3· Bayer AG· Source
Terminated
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· Phase 1/2· Amgen· Source
Completed
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment
NCT05147493· Phase 2· Hellenic Society Of Hematology· Source
Completed
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969· Phase 2· Cardior Pharmaceuticals GmbH· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
NCT05362058· Phase 3· Eli Lilly and Company· Source
Completed
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source
Completed
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
2023-509915-10-00· Phase 1· Glaxosmithkline Research & Development Limited· Source
Active, not recruiting
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
NCT04617925· Phase 2· Stichting European Myeloma Network· Source
Completed
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771· Phase 2· Incyte Corporation· Source
Completed
Effectiveness of Wound Drains for the Prevention Of Surgical sITe infectION
NCT05179122· National and Kapodistrian University of Athens· Source
Completed
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939· Phase 3· GlaxoSmithKline· Source
Completed
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616· Phase 2· Amgen· Source
Completed
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414· Phase 1/2· Celgene· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT03900598· Phase 1· Janssen Research & Development, LLC· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Completed
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
NCT03568097· Phase 2· Hellenic Cooperative Oncology Group· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Completed
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
NCT03555422· Phase 3· Karyopharm Therapeutics Inc· Source
Completed
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
NCT03201965· Phase 3· Janssen Research & Development, LLC· Source
Completed
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
NCT03173560· Phase 2· Eisai Inc.· Source
Completed
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03141177· Phase 3· Bristol-Myers Squibb· Source
Completed
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
NCT02632409· Phase 3· Bristol-Myers Squibb· Source